Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David MacDonald

Showing results (101-110 of 141) with videos related to

Pageof 15
Sort By:
Epilepsy Research and Treatment|March 15, 2014
Epilepsy surgery series: a study of 502 consecutive patients from a developing countryAbdulaziz Alsemari, Faisal Al-Otaibi, Salah Baz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2019
First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up StudyIan W Flinn, Richard van der Jagt, Brad Kahl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 4, 2011
Bortezomib ADDED to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials GroupLaurie H Sehn, David MacDonald, Sheldon Rubin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2021
Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III Innovate<sup>TM</sup> TrialJudith Trotman, Christian Buske, Alessandra Tedeschi, et al.
Frontiers in Neuroinformatics|August 27, 2016
MINC 2.0: A Flexible Format for Multi-Modal ImagesRobert D Vincent, Peter Neelin, Najmeh Khalili-Mahani, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 16, 2016
Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell LymphomaJohn M Burke, Richard H C van der Jagt, Brad S Kahl, et al.
British Journal of Anaesthesia|August 12, 2020
Frailty and long-term postoperative disability trajectories: a prospective multicentre cohort studyDaniel I McIsaac, Monica Taljaard, Gregory L Bryson, et al.
Annals of Surgery|July 27, 2018
Frailty as a Predictor of Death or New Disability After Surgery: A Prospective Cohort StudyDaniel I McIsaac, Monica Taljaard, Gregory L Bryson, et al.
Leukemia & Lymphoma|October 11, 2018
A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY.15 study†Tony Reiman, Kerry J Savage, Michael Crump, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 7, 2017
The Senior Toronto Oncology Panel (STOP) Study: Research Participation for Older Adults With Cancer and CaregiversMartine T E Puts, Schroder Sattar, Takami Fossat, et al.
Pageof 15

Showing results (101-110 of 141) with videos related to

Sort By:
Pageof 15
Epilepsy Research and Treatment|March 15, 2014
Epilepsy surgery series: a study of 502 consecutive patients from a developing countryAbdulaziz Alsemari, Faisal Al-Otaibi, Salah Baz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2019
First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up StudyIan W Flinn, Richard van der Jagt, Brad Kahl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 4, 2011
Bortezomib ADDED to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials GroupLaurie H Sehn, David MacDonald, Sheldon Rubin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2021
Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III Innovate<sup>TM</sup> TrialJudith Trotman, Christian Buske, Alessandra Tedeschi, et al.
Frontiers in Neuroinformatics|August 27, 2016
MINC 2.0: A Flexible Format for Multi-Modal ImagesRobert D Vincent, Peter Neelin, Najmeh Khalili-Mahani, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 16, 2016
Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell LymphomaJohn M Burke, Richard H C van der Jagt, Brad S Kahl, et al.
British Journal of Anaesthesia|August 12, 2020
Frailty and long-term postoperative disability trajectories: a prospective multicentre cohort studyDaniel I McIsaac, Monica Taljaard, Gregory L Bryson, et al.
Annals of Surgery|July 27, 2018
Frailty as a Predictor of Death or New Disability After Surgery: A Prospective Cohort StudyDaniel I McIsaac, Monica Taljaard, Gregory L Bryson, et al.
Leukemia & Lymphoma|October 11, 2018
A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY.15 study†Tony Reiman, Kerry J Savage, Michael Crump, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 7, 2017
The Senior Toronto Oncology Panel (STOP) Study: Research Participation for Older Adults With Cancer and CaregiversMartine T E Puts, Schroder Sattar, Takami Fossat, et al.
Pageof 15